UltraJect

Company: Mallinckrodt Group
Approval Status: Approved August 1996
Treatment for: chronic pain
Areas: Neurology & Nervous System; Cancer & Oncology

| General Information |

General Information

The UltraJect Morphine Sulfate Injection has been approved in two dosage strengths. It is the first terminally sterilized plastic syringe intended for use with patient-controlled pain management. The injection system allows patients to dispense their own medication. Morphine sulfate is used to treat moderate to severe pain such as that associated with post-operative surgical pain or cancer.

< back to top

UltraJect Drug Information

The Ultraject drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.